Scientific article

Progrès dans l'immunothérapie des tumeurs cérébrales : difficultés et perspectives

Published inRevue médicale suisse, vol. 12, no. 516, p. 828-831
Publication date2016

Glioblastomas are highly aggressive tumors. Their prognosis remain poor despite standard therapies combining surgery, radiation and temozolomide based chemotherapy. Among innovating strategies, there is a major interest for immunotherapy. During the past 3 decades, there has been a general scepticism concerning the efficacy of this approach. But the latest achievements, such as immune checkpoint inhibitors in solid tumors, and adoptive cell therapy in hematologic malignancies, have radically changed the face of the field and have already an impact on the daily practice. To which extent these advances have an impact for brain tumors also? This article aims to present the principal clinical applications of the various immune therapies currently under investigation in neurooncology and give an insight on the future perspectives in the field.

  • Brain Neoplasms/pathology/therapy
  • Glioblastoma/pathology/therapy
  • Humans
  • Immunotherapy/methods
  • Prognosis
Citation (ISO format)
MIGLIORINI, Denis, DIETRICH, Pierre-Yves. Progrès dans l’immunothérapie des tumeurs cérébrales : difficultés et perspectives. In: Revue médicale suisse, 2016, vol. 12, n° 516, p. 828–831.
Main files (1)
Article (Published version)
ISSN of the journal1660-9379

Technical informations

Creation09/26/2017 5:40:00 PM
First validation09/26/2017 5:40:00 PM
Update time03/15/2023 2:03:52 AM
Status update03/15/2023 2:03:52 AM
Last indexation10/19/2023 6:37:09 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack